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Abstract
The use of plants for medicinal purposes dates back thousands of years but genetic engineering of plants
to produce desired biopharmaceuticals is much more recent. As the demand for biopharmaceuticals is
expected to increase, it would be wise to ensure that they will be available in significantly larger amounts,
on a cost-effective basis. Currently, the cost of biopharmaceuticals limits their availability. Plant-derived
biopharmaceuticals are cheap to produce and store, easy to scale up for mass production, and safer than
those derived from animals. Here, we discuss recent developments in this field and possible
environmental concerns.

Disciplines
Dentistry

Comments
At the time of publication, author Henry Daniell was affiliated with the University of Central Florida.
Currently, he is a faculty member at the School of Dental Medicine at the University of Pennsylvania

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/dental_papers/283

HHS Public Access
Author manuscript
Author Manuscript

Trends Plant Sci. Author manuscript; available in PMC 2017 July 04.
Published in final edited form as:
Trends Plant Sci. 2001 May ; 6(5): 219–226.

Medical molecular farming: production of antibodies,
biopharmaceuticals and edible vaccines in plants
Henry Daniell*,
Dept Molecular Biology and Microbiology and Center for Discovery of Drugs and Diagnostics,
University of Central Florida, 12 722 Research Parkway, Orlando, FL 32826, USA

Author Manuscript

Stephen J. Streatfield, and
ProdiGene, 101 Gateway Boulevard, College Station, TX 77845, USA
Keith Wycoff
Planet Biotechnology, 2462 Wyandotte Street, Mountain View, CA 94043, USA

Abstract

Author Manuscript

The use of plants for medicinal purposes dates back thousands of years but genetic engineering of
plants to produce desired biopharmaceuticals is much more recent. As the demand for
biopharmaceuticals is expected to increase, it would be wise to ensure that they will be available in
significantly larger amounts, on a cost-effective basis. Currently, the cost of biopharmaceuticals
limits their availability. Plant-derived biopharmaceuticals are cheap to produce and store, easy to
scale up for mass production, and safer than those derived from animals. Here, we discuss recent
developments in this field and possible environmental concerns.
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Research in the past few decades has revolutionized the use of therapeutically valuable
proteins in a variety of clinical treatments. Because most genes can be expressed in many
different systems, it is essential to determine which system offers the most advantages for
the production of the recombinant protein. The ideal expression system would be the one
that produces the most safe, biologically active material at the lowest cost. The use of
modified mammalian cells with recombinant DNA techniques has the advantage of resulting
in products that are identical to those of natural origin; however, culturing these cells is
expensive and can only be carried out on a limited scale. The use of microorganisms such as
bacteria permits manufacture on a larger scale, but introduces the disadvantage of producing
products that differ appreciably from the products of natural origin. For example, proteins
that are usually glycosylated in humans are not glycosylated by bacteria. Furthermore,
human proteins that are expressed at high levels in E. coli frequently acquire an unnatural
conformation accompanied by intracellular precipitation, owing to lack of proper folding
and disulfide bridges.
The production of recombinant proteins in plants has many potential advantages for
generating biopharmaceuticals relevant to clinical medicine. First, plant systems are more
economical than industrial facilities using fermentation or bioreactor systems. Second, the
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technology is already available for harvesting and processing plants and plant products on a
large scale. Third, the purification requirement can be eliminated when the plant tissue
containing the recombinant protein is used as a food (edible vaccines). Fourth, plants can be
directed to target proteins into intracellular compartments in which they are more stable, or
even to express them directly in certain compartments (chloroplasts). Fifth, the amount of
recombinant product that can be produced approaches industrial-scale levels. Last, health
risks arising from contamination with potential human pathogens or toxins are minimized.

Antibody production in plants

Author Manuscript

In the decade since the expression and assembly of immunoglobulin (Ig) heavy and light
chains into functional antibodies was first shown in transgenic tobacco, plants have proven
to be versatile production systems for many forms of antibodies. These include full-sized
IgG and IgA, chimeric IgG and IgA, secretory IgG and IgA, single-chain Fv fragments
(scFv), Fab fragments and heavy-chain variable domains. Recently, this list has been
extended to include bispecific antibodies, which are made by the genetic fusion of two
different scFvs via a flexible peptide linker1. Plants have great potential as a virtually
unlimited source of inexpensive monoclonal antibodies (dubbed ‘plantibodies’) for human
and animal therapeutics (Table 1).

Author Manuscript
Author Manuscript

There is not yet a consensus as to the best plant species or tissue for commercial antibody
production. Most antibodies expressed to date have been in tobacco, although recently
potatoes, soybean, alfalfa, rice and wheat have also been used successfully2–6. The major
advantage of using green tissue (tobacco, alfalfa, soybean) is sheer productivity. Both alfalfa
and tobacco can support several crops (cuttings) per year, with potential annual biomass
yields of 25 tonne ha−1 and >100 tonne ha−1, respectively. By contrast, the maximum yields
of wheat, rice and corn seed are ~3 tonne ha−1, 6 tonne ha−1 and 12 tonne ha−1, respectively.
Other advantages of tobacco include its relative ease of genetic manipulation, production of
large numbers of seeds (up to a million per plant) and an impending need to explore
alternate uses for this hazardous crop. However, seeds are likely to have fewer phenolic
compounds and a less complex mixture of proteins and lipids than green leaves, which might
be an advantage in purification. Another advantage of seeds or tubers is their ability to be
stored for long periods. Levels of scFv in rice seeds did not show a significant decline after
storage at room temperature for six months5. Potato tubers in cold storage for 18 months lost
only 50% of functional antibody2. For short periods of time (five to seven days), dried
tobacco and alfalfa leaves can also be stored with little loss of scFv (Ref. 7) or IgG
antibody4. Purification of antibody from stored plant material has the advantages that the
processing facility need not be near the field and can be used continually all year, rather than
for just a few large batches.
To date, only four antibodies have been made in plants that are potentially useful as human
therapeutics. Only one of these has been tested in humans: a chimeric secretory IgG–IgA
antibody against a surface antigen of Streptococcus mutans, the primary causal agent of
tooth decay. This tobacco-produced antibody was applied topically to teeth and found to be
as effective as an IgG produced in a murine hybridoma at preventing recolonization by S.
mutans8. The second antibody, a humanized anti-herpes-simplex virus (HSV) antibody made
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in soybean, was effective in the prevention of vaginal HSV-2 transmission in a mouse
model3. Its activity was indistinguishable both in vitro and in vivo from the monoclonal
antibody produced in cell culture. A third antibody, against carcinoembryonic antigen
(CEA), has recently been expressed in rice and wheat5. CEA, a cell-surface glycoprotein, is
one of the best-characterized tumor-associated antigens. Antibodies against CEA are used
for in vivo tumor imaging, as well as in antibody-based cancer therapy. Levels of scFv in
seeds did not show a significant decline after storage at room temperature for six months.
This same antibody has been expressed in a rice cell culture6.

Author Manuscript

The fourth antibody is an example of both a novel use of plant-produced antibodies and an
alternative production system. A plant virus vector has been used to produce a tumorspecific vaccine transiently in tobacco for the treatment of lymphoma9. The antibody genes
for expression of an scFv were derived from a mouse B-cell lymphoma. The plant-produced
scFv was used to immunize mice, which generated anti-idiotypic antibodies (antibodies
against the binding portion of the antibody). These mice were protected against infection by
the lymphoma that produced the original antibody. Other groups have used modified plant
viral vectors to produce therapeutically useful antibodies in plants, including an antibody
against the colorectal-cancer-associated antigen GA733-2 (Ref. 10). Although these vectors
might find limited usefulness if the rapid production of an antibody is necessary (perhaps in
greenhouse production), their acceptability to regulatory agencies (e.g. the US Food and
Drug Administration, Dept of Agriculture and Environmental Protection Agency) has not
been tested.

Author Manuscript

There are no plantibodies yet in commercial production, therefore estimates of cost are
difficult to find and involve many assumptions. The costs of producing an IgG from alfalfa
grown in a 250 m2 greenhouse are estimated to be US$500–600 g−1, compared with US
$5000 g−1 for the hybridoma-produced antibody4. Planet Biotechnology (Mountain View,
CA, USA) has compared the cost per gram of purified IgA made by cell culture, transgenic
goats, grain (7.5 tonne ha−1) and green biomass (120.0 tonne ha−1) (Fig. 1). Expression
levels will have a significant impact on the costs but, at the best expression level reported
[500 μg g−1 leaf for a secretory IgA (Ref. 11)], the final cost should be well below US$50
g−1. This significantly undercuts the costs of cell culture (US$1000 g−1) or transgenic
animal production systems (US$100 g−1). The biggest component of cost with plantibodies
will be purification. However, expression in seeds of rice and wheat5 opens up the possibility
of oral administration of some therapeutic antibodies without the need for expensive
purification.

Author Manuscript

Some of the properties of Igs depend on their glycosylation (e.g. binding to monocyte Fc
receptors). There is one conserved N-glycosylation site in the CH2 domain of IgG. The
structures of N-linked glycans on plant- and murine-produced Guy’s 13 (an IgG1) have been
determined and compared12. The plantibody N-glycans were more structurally diverse, with
40% being of the high-mannose type. The other 60% of the plantibody oligosaccharides had
β-(1,2)-xylose and α-(1,3)-fucose linked to the Man3GlcNAc2 core. These linkages are
typical of plants but are not found in mammalian N-glycans. The plantibody also lacked
sialic acid, which represented ~10% of the sugar content of the mouse monoclonal antibody.
These differences in glycan structure appear to have no effect on antigen binding or affinity
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in vitro3,4,11,13 and might not be significant in vivo either. An IgG produced in alfalfa had a
serum half-life in Balb/c mice that was indistinguishable from that of the hybridomaproduced antibody4. However, there is some concern about the potential immunogenicity
and allergenicity of plantibodies used as human therapeutics. For mucosal applications, this
is not likely to present problems for most people because plant glycoproteins are ubiquitous
in the human diet. There has been no evidence of allergic reaction or of a human anti-mouse
antibody (HAMA) response in 60 patients receiving topical oral application of a secretory
IgA specific to S. mutans8.

Edible vaccines

Author Manuscript

Proteins of microbial and viral pathogens were some of the earliest examples chosen to show
the feasibility of transgenic plant expression systems14–17. The rationale was that key
immunogenic proteins of major pathogens could be synthesized in plant tissues and then fed
as edible subunit vaccines to humans or commercially important animals. The proof of this
concept has since been shown using several bacterial and viral proteins (Table 2). The
practical aspects of choosing particular foodstuffs in which to deliver defined doses of a
vaccine are being explored, and efforts are under way to establish clear regulatory paths for
the development of edible vaccines.

Author Manuscript

Oral delivery of vaccines is an attractive alternative to injection, largely for reasons of low
cost and easy administration. The chances of acquiring mucosal immunity against infectious
agents that enter the body across a mucosal surface are also increased with oral vaccines.
However, a major concern with oral vaccines is the degradation of protein components in the
stomach and gut before they can elicit an immune response. To guard against degradation,
several delivery vehicles have been developed to ferry intact proteins to the gut. These
include recombinant strains of attenuated microorganisms, bioencapsulation vehicles such as
liposomes and transgenic plant tissues.

Author Manuscript

Early work with plant-based subunit vaccines used the readily transformed species tobacco,
potato and tomato14–18. However, the most attractive species for expressing subunit vaccine
components should have high levels of soluble protein that is stable during storage; seed
crops such as cereals are particularly suitable. The embryo fraction is rich in soluble protein
and can easily be separated from other seed tissue to increase the concentration of antigen
and thus decrease the dose size. The choice of crop defines the type of material to be fed.
Many plant tissues can be consumed raw but others must be processed. Processing facilitates
the creation of a homogeneous sample, enabling a defined dose size, but it is important that
any heat or pressure treatments involved do not destroy the antigen. Alternative processing
steps have been applied to a candidate vaccine component against enterotoxigenic strains of
E. coli that consists of the B subunit of the heat-labile toxin (Lt-B) expressed in corn. A
typical 1 mg dose of Lt-B could be delivered in an embryo fraction, to decrease the volume
of the dose, or in a ‘cooked’ whole corn snack, to increase palatability and enhance stable
storage (Fig. 2). In this case, neither treatment degrades the antigen. For commercial animal
vaccines, the relevant protein can be expressed in a plant tissue that constitutes a major
proportion of the diet, and heat and pressure treatments are not necessary.
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Some key examples that illustrate the range of candidate proteins under investigation and
plant expression systems being used are given in Table 2. Plant-expressed antigens have
been shown to able to induce mucosal and serum immune responses when administered
parenterally or orally to experimental animals and, in some test cases, they have offered
protection against a subsequent pathogen challenge or challenge model14,16,19–24. A few of
these vaccine candidates have been successfully tested in clinical trials or, where
appropriate, in commercial or native animal trials25–30. Thus, edible vaccines delivered in
plant tissues or processed plant products show great potential for efficacy in target
organisms. The bioencapsulation of Lt-B in transgenic corn material results in an increased
mucosal immune response compared with that achieved with naked antigen when fed to
mice30. Presumably, this is because the antigen is protected from degradation in the gut, and
it augurs well for the development of plant-based edible vaccines.

Author Manuscript

The quantity of plant tissue constituting a vaccine dose must be of a practical size for
consumption. Thus, achieving a high level of expression is crucial. The expression of
vaccine components in plants has been increased by using a range of leader and
polyadenylation signals31 and by optimizing codon usage for plants22,29,30. Expression
could also be raised through crosses of transformed lines to various genetic backgrounds, an
approach that has been successfully applied to boost protein production in corn. It is also
important that any vaccine component should be present in its native form in the transgenic
plant tissue. This has been assessed in several cases by examining the size of the synthesized
protein, its ability to form higher-order complexes that mirror microbial or viral structures
and, where relevant, by showing an enzymatic or receptor-binding activity14,16–18,22,24,29.

Author Manuscript

The stability of heterologous proteins and the assembly of multisubunit structures depend on
the cellular environment and therefore on the subcellular location. Favored locations for the
expression of selected subunit vaccine components are the cell surface and the endoplasmic
reticulum and Golgi body14,18,29,31,32. As with antibodies, transient expression systems (in
which candidate vaccine sequences are incorporated into plant viral surface proteins) have
also been investigated extensively and high levels of expression have been achieved. A
related strategy to that of edible vaccines uses transgenic plants expressing autoantigens,
whereby a large oral dose of an autoantigen can inhibit the development of an autoimmune
disease through the mechanism of oral tolerance. This approach has been successful in a
mouse model for diabetes33.

Plant-derived biopharmaceuticals and human proteins
Author Manuscript

Generally, levels of pharmaceutical proteins produced in transgenic plants have been less
than the 1% of total soluble protein that is needed for commercial feasibility if the protein
must be purified34. Plant-derived recombinant hepatitis-B surface antigen induced only a
low level serum antibody response in a small human study, probably reflecting the low level
of expression (1–5 ng g−1 fresh weight) in transgenic lettuce27. In spite of recent
improvements in expression levels in potato with a view to clinical trials31, expression levels
should be increased further for practical purposes. Also, even though Norwalk virus capsid
protein expressed in potatoes caused oral immunization when consumed as food, expression
levels are too low for large-scale oral administration (0.37% of total soluble protein)16,26.
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Expression of genes encoding other human proteins in transgenic plants has been
disappointingly low: human serum albumin, 0.020% total soluble protein; human protein C,
0.001% total soluble protein; erythropoietin,~0.003% total soluble protein; and human
interferon-β, <0.001% fresh weight (Table 3). A synthetic gene coding for the human
epidermal growth factor was expressed only up to 0.001% of total soluble protein in
transgenic tobacco35,36. In spite of several successful reports of high-level expression of
non-human proteins (e.g. phytase, glucanase) via the nuclear genome, there is a great need
to increase expression levels of human blood proteins to enable the commercial production
of pharmacologically important proteins in plants.

Chloroplast transgenic system

Author Manuscript

One alternative approach is to express foreign proteins in chloroplasts of higher plants.
Foreign genes have been integrated into the tobacco chloroplast genome, giving up to 10 000
copies per cell and resulting in the accumulation of recombinant proteins at up to 47% of the
total soluble protein37. Chloroplast transformation uses two flanking sequences that, through
homologous recombination, insert foreign DNA into the spacer region between the
functional genes of the chloroplast genome, thus targeting the foreign genes to a precise
location. This eliminates the ‘position effect’ upon expression that is frequently observed in
transgenic plants with genes inserted into the nuclear genome. In addition, gene silencing
has not been observed with chloroplast transformation, whereas it is a common phenomenon
with nuclear transformation.

Author Manuscript

Chloroplast genetic engineering is an environmentally friendly approach, minimizing several
environmental concerns38,39. Importantly, chloroplasts can process eukaryotic proteins,
including enabling correct folding and the formation of disulfide bridges. Chaperonin
proteins are present in chloroplasts and might function in the folding and assembly of nonnative proteins of both prokaryotic and eukaryotic origins. Also, chloroplast proteins are
activated by disulfide bond oxidation–reduction cycles using the plastid thioredoxin
system40 or protein disulfide isomerase41. Accumulation of large quantities of a fully
assembled form of human somatotropin with the correct disulfide bonds (7% total soluble
protein)42 provides strong evidence for hyperexpression and assembly of pharmaceutical
proteins using this approach. Such folding and assembly of foreign proteins should eliminate
the need for expensive in vitro processing of pharmaceutical proteins produced in
recombinant organisms. For example, 60% of the total operating cost for the commercial
production of human insulin in E. coli is associated with in vitro processing (formation of
disufide bridges and cleavage of methionine)43.

Author Manuscript

Novel biopharmaceutical purification strategies
Purification is likely to represent most of the cost of biopharmaceutical production in plants.
For the commercial production of insulin in E. coli, chromatography accounts for 30% of
operating expenses and 70% of equipment costs43. Therefore, new approaches are necessary
to minimize or eliminate chromatography in the production of pharmaceutical proteins. One
successful recent approach is targeting pharmaceutical proteins to seed oil bodies. This was
shown with hirudin, an anticoagulant first isolated from the leech Hirudo medicinalis. An
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oleosin–hirudin fusion protein has been targeted to oil bodies of Brassica napus seeds and
purified by flotation centrifugation for commercial production in Canada44.

Author Manuscript

Another novel approach is the use of GVGVP as a fusion protein to facilitate single-step
purification without the use of chromatography. GVGVP is a protein-based polymer
encoded by synthetic genes. At low temperatures, it exists as an extended molecule but,
upon raising the temperature above the transition range, the polymer hydrophobically folds
into dynamic structures called β-spirals that further aggregate by hydrophobic association to
form twisted filaments45. Using this approach, single-step purification of an insulin–polymer
fusion has recently been shown. Inverse temperature transition offers several advantages,
including facilitating the scale-up of purification from grams to kilograms (O. CarmonaSanchez and H. Daniell, unpublished). Yet another recent approach is the use of a
chaperonin protein to fold foreign proteins into cuboidal crystals, allowing their purification
in a single step by centrifugation37. One additional advantage of this method is the
protection of foreign proteins from cellular proteases.

Future perspectives

Author Manuscript

Plant-derived biopharmaceuticals should meet the same standards of safety and performance
as other production systems. However, many herbal medicines are now exempt from such
close scrutiny and are not required to meet the same standards because of their classification
as nutritional supplements. Because several environmental concerns have been raised by
interest groups to confuse public perception, it is of paramount importance that regulating
agencies distinguish between real and perceived public concerns (scientific versus nonscientific). If biopharmaceuticals that are potentially harmful are capable of persisting in the
environment and might accumulate in non-target organisms, precautionary measures should
be taken. Induction of biopharmaceutical production after harvesting (as was done in the
case of glucocerebrosidase36) might be one approach to minimize environmental exposure,
provided that the use of viral vectors does not introduce additional environmental or
regulatory concerns. Expression of potentially harmful proteins in a form that must be
treated for activation might minimize the risk of exposure. For example, hirudin is produced
as a fusion protein and is inactive in this form; it is activated only after it is purified from
seeds36.

Author Manuscript

Another hotly debated environmental concern has been the outcrossing of transgenic pollen
to weeds or related crops38,39. Expression of harmful pharmaceutical proteins in non-target
plants resulting from such outcrosses might create public concern and negative perception.
Several gene containment methods are currently being investigated, including apomixis,
incompatible genomes, transgenic mitigation, control of seed dormancy or shattering,
suicide genes, infertility barriers, male sterility and maternal inheritance. Engineering
foreign genes via the chloroplast genome has been shown to contain transgenes effectively,
although there are a few exceptions in which the chloroplast genome shows biparental
inheritance (e.g. pines)46. As an example of an alternative strategy, RNAse genes have been
expressed under the control of a tissue-specific promoter to destroy the tapetum selectively
during anther development, resulting in male sterile plants47.
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There is also concern over the expression of harmful proteins in transgenic pollen. For
example, the controversial observation of the toxic effect of Bacillus thuringiensis (Bt) corn
pollen on milkweeds (Asclepias spp.) fed to monarch butterfly larvae had a significant
impact on public perception, even though the validity of this study has been repeatedly
questioned. Engineering biopharmaceuticals via the chloroplast genome might be a solution.
Although the Cry protein of Bt was expressed at high levels in leaves (up to 47% of total
soluble protein), no toxicity was observed when milkweeds dusted with transgenic pollen
were fed to monarch butterfly larvae37. However, to date, chloroplast genetic engineering
has been shown only in tobacco and potato. More recently, several academic and industrial
laboratories have initiated projects to extend this technology to other useful crops. Also,
there are no reports of the production of glycoproteins in transgenic chloroplasts. Another
public concern is the presence of antibiotic resistance genes or their products (which are
used as selective markers) in edible parts of genetically modified crops. However, several
approaches are now available to generate plants with transgenes in their nuclear48 or
chloroplast49 genomes without the use of antibiotic selection.
Practical considerations will dictate the choice of biopharmaceutical proteins and the crop in
which they are to be produced. These include yield, storage conditions, containment
properties, initial set up and running costs, purification strategies, size of the market,
environmental concerns, public perception and competing technologies. Access to several
alternative approaches to optimize protein synthesis in plants in an environmentally sound
manner augurs well for the safe production of biopharmaceuticals in transgenic plants and
for greater availability of these proteins to populations requiring them.
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Fig. 1.

Costs per gram for purified immunoglobulin A produced by different expression systems.
Costs for mammalian cell culture are derived from industry costs for cell culture and
purification facilities. Costs for transgenic goats are derived from publicly available
estimates from Genzyme Transgenics (Farmingham, MA, USA). Costs for plants compare
green biomass (120.0 tonne ha−1) and seed production (7.5 tonne ha−1). Cost differences are
based primarily on production costs, and it was assumed that purification costs and losses
during purification will be the same for all systems.
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Alternative forms of delivery of a corn-based edible vaccine, produced by Prodigene
(College Station, TX, USA). Transgenic corn kernels corresponding to a typical 1 mg dose
of the B subunit of E. coli heat-labile toxin (Lt-B) (a), can be processed to generate a
palatable whole corn snack of the same mass (b), or fractionated to yield an embryo or germ
component in which the antigen is about six times more concentrated (c). The exact size of
an administered dose depends on the expression level attained with a particular line of corn.
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CaMV 35S
CaMV 35S
Maize ubiquitin
Maize ubiquitin
Enhanced CaMV 35S
Enhanced CaMV 35S

TMV subgenomic coat
protein promoter
TMV subgenomic
promoter U5 CP
CaMV 35S

Dental caries; streptococcal antigen I or
II

Diagnostic; anti-human IgG

Cancer treatment; carcinoembryonic
antigen

Cancer treatment; carcinoembryonic
antigen

Cancer treatment; carcinoembryonic
antigen

Cancer treatment; carcinoembryonic
antigen

B-cell lymphoma treatment; idiotype
vaccine

Colon cancer; surface antigen

Herpes simplex virus 2

FW, fresh weight.

TSP, total soluble protein.

c

b

SIgA, secretory IgA.

a

Promoter

38C13 (scFv)

Rice α-amylase

Tobacco extensin signal
peptide

Anti-HSV-2 (IgG)

CO17-1A (IgG)

T84.66 (IgG)

TMV Ω leader; murine IgG
signal peptides; KDEL

Murine IgG signal peptide;
KDEL

ScFvT84.66 (ScFv)

ScFvT84.66 (ScFv)

ScFvT84.66 (ScFv)

Not reported

Not reported

Nicotiana benthamiana
Soybean

30.0 μg/g leaves

1.0 μg/g leaves

27.0 μg/g leaves

29.0 μg/g leaves; 32.0 μg/g
seed; 3.8 μg/g callus

3

10

9

13

5

5,6

5

4

1.0% TSPc
900.0 ng/g leaves; 1.5 μg/g
seed

8,11

Refs

500 μg/g FWb leaves

Expression levels

Nicotiana benthamiana

Nicotiana tabaccum
(transiently with
Agrobacterium infiltration)

Rice

Rice

Wheat

Alfalfa

Nicotiana tabacum

Guy’s 13 (SIgA)a
C5-1 (IgG)

Plant

Antibody name or
type

Murine IgG signal peptide;
KDEL

Murine IgG signal peptide;
KDEL

Murine IgG signal peptide;
KDEL

Murine IgG signal peptides

Murine IgG signal peptides

Signal sequences
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Heat-labile toxin B-subunit
Heat-labile toxin B-subunit
Heat-labile toxin B-subunit
Cholera toxin B-subunit

Envelope surface protein
Envelope surface protein
Envelope surface protein
Envelope surface protein
Capsid protein
Capsid protein
Glycoprotein
Glycoprotein B
VP60
VP1
VP1
Glycoprotein S
Glycoprotein S
Glycoprotein S

Enterotoxigenic E. coli (humans)

Enterotoxigenic E. coli (humans)

Enterotoxigenic E. coli (humans)

Vibrio cholerae (humans)

Hepatitis B virus (humans)

Hepatitis B virus (humans)

Hepatitis B virus (humans)

Hepatitis B virus (humans)

Norwalk virus (humans)

Norwalk virus (humans)

Rabies virus (humans)

Human cytomegalovirus (humans)

Rabbit hemorrhagic disease virus (rabbits)

Foot-and-mouth disease virus (agricultural
domestic animals)

Foot-and-mouth disease virus (agricultural
domestic animals)

Transmissible gastroenteritis coronavirus (pigs)

Transmissible gastroenteritis coronavirus (pigs)

Transmissible gastroenteritis coronavirus (pigs)

FW, fresh weight.

b

TSP, total soluble protein.

a

Protein or peptide expressed

Source of the protein and target species for
the vaccine

Maize

<0.01% FW

0.20% TSP

0.06% TSP

Arabidopsis
Tobacco

Not given

Not given

Arabidopsis
Alfalfa

0.30% TSP

<0.02% TSP

1.00% TSP

0.37% TSP

0.23% TSP

<0.01% FW

Potato

Tobacco

Tomato

Potato

Tobacco

Lettuce

<0.01% FW

Lupin (Lupinus spp.)

Protective when administered orally

Intact protein and immunogenic when administered by
injection

Immunogenic when administered by injection

Immunogenic and protective when administered by
injection or orally

Immunogenic and protective when administered by
injection

Immunogenic and protective when administered by
injection

Immunologically related protein

Intact protein

Virus-like particles form and immunogenic when
administered orally

Intact protein and virus-like particles form,
immunogenic when administered orally

Immunogenic when administered orally

Immunogenic when administered orally

Immunogenic when administered orally

<0.01% FWb

Potato

Intact protein forms multimers, has receptor- binding
activity and is immunogenic and protective when
administered orally

Immunogenic and protective when administered orally

Receptor-binding activity and immunogenic and
protective when administered orally

Intact protein forms multimers and is immunogenic
when administered orally

Integrity, immunogenicity and protective capacity
of the vaccine

Virus-like particles form and extracted protein is
immunogenic when administered by injection

0.30% TSP

Not given

0.19% TSP

<0.01% TSPa

Maximum
recorded
expression level
in planta

<0.01% TSP

Tobacco

Potato

Maize

Potato

Tobacco

Plant expression system

Proteins with applications for human or animal vaccines and expressed by transgenic plants
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30

29

21

24

20

28

32

17

16,26

16

27

27

31

15,23

18,19

30

14,22,25

14
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The production of biopharmaceuticals for human health in transgenic plants
Plant host

Protein

Expression levels

Refsa

Anticoagulant

Tobacco

Human protein C

<0.01% TSPb

36

Thrombin inhibitor

Canola (Brassica napus)

Human hirudin

0.30% seed protein

36

Neutropenia

Tobacco

Human granulocyte-macrophage colonystimulating factor

Not reported

50

Growth hormone

Tobacco
Tobacco

Human somatotropin, chloroplast
Nuclear expression

7.00% TSP
<0.01% TSP

42
42

Anemia

Tobacco

Human erythropoietin

<0.01 TSP

34

Antihyperanalgesic by opiate
activity

Arabidopsis

Human enkephalins

0.10% seed protein

34

Wound repair and control of cell
proliferation

Tobacco

Human epidermal growth

<0.01% TSP

36

Hepatitis C and B treatment

Rice, turnip (Brassica rapa)
Tobacco

Human interferon-α
Human interferon β

Not reported
<0.01% fresh weight

36
34

Liver cirrhosis, burns, surgery

Tobacco

Human serum albumin

0.02% TSP

34

Blood substitute

Tobacco

Human hemoglobin α, β

0.05% seed protein

36

Collagen

Tobacco

Human homotrimeric collagen

<0.01% fresh weight

51

Cystic fibrosis, liver disease and
hemorrhage

Rice

Human α-1-antitrypsin

Not reported

50

Trypsin inhibitor for
transplantation surgery

Maize

Human aprotinin

Not reported

50

Antimicrobial

Potato

Human lactoferrin

0.10% TSP

52

Hypertension

Tobacco, tomato

Angiotensin-converting enzyme

Not reported

50

HIV therapies

Nicotiana bethamiana

α-Tricosanthin from TMV-U1 Subgenomic
coat protein

2.00% TSP

50

Gaucher’s disease

Tobacco

Glucocerebrosidase

1.00–10.00% TSP

36

Potential application or
indication
Human proteins
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Non-human proteins
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a

Because of space limitation, reviews that cite original citations are provided.

b

TSP, total soluble protein.
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